Amyloid β protein levels in cerebrospinal fluid are elevated in early‐onset Alzheimer's disease

Tamiko Nakamura, Mikio Shoji, Yasuo Harigaya, Mitsunori Watanabe, Kenji Hosoda, Tobun T. Cheung, Lillian M. Shaffer, Todd E. Golde, Linda H. Younkin, Steven G. Younkin, Shunsaku Hirai

Research output: Contribution to journalArticlepeer-review

94 Scopus citations


The 4‐kd amyloid β prrotein (Aβ) deposited as amyloid in Alzheimer's disease (AD) is produced and released by normal proteolytic processing of the amyloid β protein precursor (βAPP) and is readily detected in cerebrospinal fluid (CSF). Here, we present the levels of Aβ in CSF from a total of 95 subjects, including 38 patients with AD, 14 with early‐onset AD and 24 with late‐onset AD, 25 normal control subjects, and 32 patients with other neurological diseases. The level of Aβ decreased with normal aging, and there was a significant elevation in the level of Aβ in the CSF of early‐onset AD patients (4.14 ±1.37 pmol/ml, p < 0.01). Neither Mini‐Mental State nor Functional Assessment Staging were correlated with the amount of Aβ in the CSF. The Aβ/secreted form of βAPP ration was elevated, but the level of α;1‐antichymotrypsin in the CSF did not correlate with the level of CSF Aβ in early‐onset AD patients. Thus, the level of Aβ in the CSF is elevated in early‐onset AD patients and is suggested to be correlated with the pathology in the brain that characterizes AD.

Original languageEnglish (US)
Pages (from-to)903-911
Number of pages9
JournalAnnals of neurology
Issue number6
StatePublished - Dec 1994

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Amyloid β protein levels in cerebrospinal fluid are elevated in early‐onset Alzheimer's disease'. Together they form a unique fingerprint.

Cite this